NCT02398773
FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy diagnostic 2 active_not_recruiting NCT02876107
Carboplatin and Paclitaxel with or Without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer treatment 2 active_not_recruiting NCT03207529
Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer treatment 1 completed NCT03359954
Radiation Therapy Before Surgery in Treating Patients with Hormone Receptor Positive, HER2 Negative Breast Cancer No drug interventions treatment 2 active_not_recruiting NCT03872388
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy treatment 2 terminated NCT03070002
Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells treatment 2 terminated NCT02945579
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy No drug interventions treatment Not Available recruiting NCT01238133
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer treatment 1 terminated NCT03599453
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer treatment 0 completed NCT02744053
DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer diagnostic 0 active_not_recruiting NCT02648477
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer treatment 2 completed NCT02401347
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors treatment 2 completed NCT02282345
Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer treatment 2 completed NCT02971761
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer treatment 2 completed NCT03723928
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer No drug interventions health_services_research Not Available recruiting NCT02411656
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy treatment 2 active_not_recruiting NCT03566485
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer treatment 1 / 2 terminated NCT02860000
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer treatment 2 active_not_recruiting NCT02672475
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer treatment 1 completed NCT02208375
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian treatment 1 / 2 active_not_recruiting NCT03725436
ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors treatment 1 active_not_recruiting NCT00892736
Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy treatment 1 completed NCT01754519
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery No drug interventions treatment 2 terminated NCT03128619
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer treatment 1 terminated NCT02892734
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer treatment 2 terminated NCT03477396
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer treatment 2 completed NCT01276496
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery treatment 1 completed NCT03326258
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery treatment 1 / 2 withdrawn NCT02432963
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy treatment 1 active_not_recruiting NCT01928186
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer diagnostic Not Available completed NCT01319539
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer No drug interventions treatment 2 terminated NCT01145430
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer treatment 1 completed NCT02115282
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic treatment 3 active_not_recruiting NCT03633331
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer treatment 2 unknown_status NCT01750073
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer treatment 2 active_not_recruiting NCT02599194
18F-FSPG PET/CT for Cancer Patients on Therapy diagnostic 2 completed NCT00785291
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer treatment 3 completed NCT02445391
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy treatment 3 active_not_recruiting NCT01846091
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer treatment 1 completed NCT03644589
Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer treatment 2 withdrawn NCT04090567
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer treatment 2 recruiting NCT03132467
Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer treatment 0 completed NCT02780401
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission prevention 1 active_not_recruiting NCT02957968
Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca treatment 2 active_not_recruiting NCT02993068
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) No drug interventions diagnostic Not Available recruiting NCT02120469
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer treatment 1 completed NCT02774681
Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis treatment 2 terminated NCT03523195
Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors No drug interventions supportive_care Not Available completed NCT00390455
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive treatment 3 completed NCT01776008
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer treatment 2 terminated NCT03291938
IACS-010759 in Advanced Cancers No drug interventions treatment 1 completed NCT03238703
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer treatment 4 withdrawn NCT03154190
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer No drug interventions health_services_research Not Available unknown_status NCT01071564
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery treatment 1 terminated NCT03106077
Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer treatment 2 completed NCT04185311
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted treatment 1 terminated NCT01697293
PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer treatment 1 / 2 terminated NCT03691493
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis treatment 2 completed NCT01149356
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer treatment 1 terminated NCT00877500
Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy treatment 2 active_not_recruiting NCT03715959
Nipple Aspirate Fluid in Detecting Breast Cancer No drug interventions diagnostic Not Available active_not_recruiting NCT01624441
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer treatment 1 completed NCT03213041
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer treatment 2 recruiting NCT01964924
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer treatment 2 completed NCT02567396
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction treatment 1 withdrawn NCT01575522
Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer treatment 2 completed NCT03544125
Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer treatment 1 completed NCT03044730
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery treatment 2 unknown_status NCT02760030
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery treatment 2 recruiting NCT02627430
Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer treatment 1 withdrawn NCT01525966
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer treatment 2 active_not_recruiting NCT01251874
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer treatment 1 completed NCT02536794
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer treatment 2 completed NCT02037529
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer treatment 3 suspended NCT04081389
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer treatment 1 completed NCT03554044
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer treatment 1 active_not_recruiting NCT02488967
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer treatment 3 active_not_recruiting NCT03377101
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer treatment 2 withdrawn NCT02457910
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer treatment 1 / 2 terminated NCT01957514
Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy No drug interventions Not Available Not Available terminated NCT01281150
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors treatment 1 completed NCT03156309
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission prevention 1 recruiting NCT06131424
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients No drug interventions Not Available Not Available recruiting NCT04669587
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) treatment 1 / 2 unknown_status NCT04757363
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer treatment 2 active_not_recruiting NCT03206203
Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer treatment 2 active_not_recruiting NCT06284746
Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer No drug interventions treatment 2 recruiting